Insider Transactions in Q1 2021 at Quest Diagnostics Inc (DGX)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2021
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
5,574
-12.19%
|
$668,880
$120.47 P/Share
|
|
Mar 09
2021
|
Manner Carrie Eglinton SVP, Advanced Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
6,165
-16.93%
|
$708,975
$115.42 P/Share
|
|
Mar 09
2021
|
Manner Carrie Eglinton SVP, Advanced Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
13,181
+26.59%
|
$1,515,815
$115.42 P/Share
|
|
Mar 09
2021
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
8,334
-14.3%
|
$958,410
$115.42 P/Share
|
|
Mar 09
2021
|
J. E. Davis CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
16,570
+22.14%
|
$1,905,550
$115.42 P/Share
|
|
Mar 09
2021
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
5,066
-6.15%
|
$582,590
$115.42 P/Share
|
|
Mar 09
2021
|
Catherine T. Doherty EVP, Regional Businesses |
BUY
Grant, award, or other acquisition
|
Direct |
11,299
+12.07%
|
$1,299,385
$115.42 P/Share
|
|
Mar 09
2021
|
Mark Guinan Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,403
-6.73%
|
$736,345
$115.42 P/Share
|
|
Mar 09
2021
|
Mark Guinan Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
17,322
+15.4%
|
$1,992,030
$115.42 P/Share
|
|
Mar 09
2021
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
684
-2.49%
|
$78,660
$115.42 P/Share
|
|
Mar 09
2021
|
Michael J Deppe SVP, Corp. Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
1,884
+6.41%
|
$216,660
$115.42 P/Share
|
|
Mar 09
2021
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,217
-8.44%
|
$484,955
$115.42 P/Share
|
|
Mar 09
2021
|
Michael E Prevoznik SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
9,791
+16.39%
|
$1,125,965
$115.42 P/Share
|
|
Mar 09
2021
|
Stephen H Rusckowski Director |
SELL
Payment of exercise price or tax liability
|
Direct |
25,887
-8.34%
|
$2,977,005
$115.42 P/Share
|
|
Mar 09
2021
|
Stephen H Rusckowski Director |
BUY
Grant, award, or other acquisition
|
Direct |
58,368
+15.83%
|
$6,712,320
$115.42 P/Share
|
|
Feb 25
2021
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
801
-1.96%
|
$92,115
$115.49 P/Share
|
|
Feb 24
2021
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
524
-0.73%
|
$63,404
$121.19 P/Share
|
|
Feb 24
2021
|
Stephen H Rusckowski Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,319
-1.3%
|
$401,599
$121.19 P/Share
|
|
Feb 24
2021
|
Mark Guinan Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
541
-0.69%
|
$65,461
$121.19 P/Share
|
|
Feb 24
2021
|
Manner Carrie Eglinton SVP, Advanced Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
611
-2.56%
|
$73,931
$121.19 P/Share
|
|
Feb 24
2021
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
103
-0.4%
|
$12,463
$121.19 P/Share
|
|
Feb 24
2021
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
1,188
-1.42%
|
$137,808
$116.95 P/Share
|
|
Feb 24
2021
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
455
-1.07%
|
$55,055
$121.19 P/Share
|
|
Feb 24
2021
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
806
-1.9%
|
$97,526
$121.19 P/Share
|
|
Feb 23
2021
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
796
-1.1%
|
$96,316
$121.15 P/Share
|
|
Feb 23
2021
|
Stephen H Rusckowski Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,033
-1.56%
|
$487,993
$121.15 P/Share
|
|
Feb 23
2021
|
Mark Guinan Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
830
-1.05%
|
$100,430
$121.15 P/Share
|
|
Feb 23
2021
|
Manner Carrie Eglinton SVP, Advanced Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
1,017
-4.09%
|
$123,057
$121.15 P/Share
|
|
Feb 23
2021
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
159
-0.61%
|
$19,239
$121.15 P/Share
|
|
Feb 23
2021
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
693
-1.6%
|
$83,853
$121.15 P/Share
|
|
Feb 23
2021
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,250
-2.86%
|
$151,250
$121.15 P/Share
|
|
Feb 17
2021
|
Manuel O. Mendez SVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,926
+14.5%
|
-
|
|
Feb 17
2021
|
Manner Carrie Eglinton SVP, Advanced Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
4,926
+16.55%
|
-
|
|
Feb 17
2021
|
J. E. Davis CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
5,665
+11.46%
|
-
|
|
Feb 17
2021
|
Catherine T. Doherty EVP, Regional Businesses |
BUY
Grant, award, or other acquisition
|
Direct |
3,941
+5.17%
|
-
|
|
Feb 17
2021
|
Mark Guinan Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
5,665
+6.67%
|
-
|
|
Feb 17
2021
|
Michael J Deppe SVP, Corp. Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
715
+2.69%
|
-
|
|
Feb 17
2021
|
Michael E Prevoznik SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
3,202
+6.89%
|
-
|
|
Feb 17
2021
|
Stephen H Rusckowski Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,551
+7.67%
|
-
|
|
Jan 04
2021
|
Manner Carrie Eglinton SVP, Advanced Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
2,640
-11.71%
|
$314,160
$119.0 P/Share
|